RCM
CASC

RA Capital Management’s Cascadian Therapeutics, Inc. CASC Stock Holding History

RA Capital Management’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-194,294
Closed -$1.9M – 69
2015
Q1 		$1.9M Buy
+194,294
New +$1.91M 0.19% 41

Other funds holding CASC

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RA Capital Management's CASC Position: Q2 2015 in Review

RA Capital Management sold out of Cascadian Therapeutics, Inc. (CASC) in Q2 2015, closing a stake of 194,294 shares — an estimated $1.9M sold.

RA Capital Management first reported a position in CASC in Q1 2015 and held it in 1 quarter. The position peaked at $1.9M in Q1 2015. 100 funds tracked by Wall St. Rank hold CASC as of Q2 2015.

  • RA Capital Management reported no remaining Cascadian Therapeutics, Inc. position as of Q2 2015 after selling out during the quarter.
  • RA Capital Management sold 194,294 Cascadian Therapeutics, Inc. shares in Q2 2015, an estimated $1.9M.
  • RA Capital Management first reported a position in Cascadian Therapeutics, Inc. in Q1 2015 and held it in 1 quarter.
  • RA Capital Management's Cascadian Therapeutics, Inc. position peaked at $1.9M in Q1 2015.
  • 100 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q2 2015.

Based on RA Capital Management's 13F filing for Q2 2015, filed 13 Aug 2015.